A study published in the peer reviewed journal Cannabis and Cannabinoid Research and available online through the U.S. National Library of Medicine explores the effects of Cannabistilbene I (a compound found in cannabis) on Angiotensin II (Ang II)-induced cardiac hypertrophy.
The research, conducted by a team at the University of Alberta, examined how Cannabistilbene I influences cytochrome P450 (CYP) enzymes and arachidonic acid (AA) metabolic pathways, both of which play crucial roles in heart function and hypertrophy. The study is titled Effect of Cannabistilbene I in Attenuating Angiotensin II-Induced Cardiac Hypertrophy: Insights into Cytochrome P450s and Arachidonic Acid Metabolites Modulation.
Cardiac hypertrophy is a condition in which the heart muscle enlarges due to stress, potentially leading to severe cardiovascular diseases. Therapeutic interventions targeting the underlying mechanisms, such as CYP enzymes and AA metabolites, could offer new ways to manage or prevent this condition.
Continue reading